The number of people completing two doses of the COVID-19 vaccine increased by 119,384 on Monday, it reported.
Meanwhile, the number of recipients of the first vaccine dose increased by 47,165 to reach 189,694,082.
According to the task force, the number of third dose recipients climbed to 8,493,624 the same day.
People must remain disciplined in observing the health protocols, namely using masks, washing hands with soap and running water, maintaining distance, avoiding crowds, and reducing mobility even after getting vaccinated, it said.
Meanwhile, the task force reported that the number of positive COVID-19 cases increased by 34,418 on Monday, taking the total tally to 5,231,923.
The number of recovered patients increased by 39,929 to reach 4,554,711, it said.
Meanwhile, the number of deaths due to COVID-19 increased by 176, bringing the total death toll to 146,541, it added.
Earlier, the National Agency of Drug and Food Control (BPOM) had issued emergency-use authorization (EUA) for five COVID-19 vaccines for the booster vaccination program.
"Five vaccines received the EUA after an evaluation by the drug or vaccine expert team and fulfilling the existing criteria," BPOM head Penny K. Lukito informed.
The approved vaccine brands were CoronaVac produced by state-run vaccine manufacturer PT Bio Farma, Pfizer, AstraZeneca, Moderna, and Zifivax, she said.
The homologous vaccine CoronaVac can be administered as a booster to people aged 18 years six months after the primary vaccination, she added.
Related news: Complete COVID-19 eradication impossible: epidemiologist
“The immunogenicity (test result) shows an increase in neutralizing antibody titer up to 21–35 times some 28 days after the provision of the CoronaVac booster vaccine to the adult recipient," she pointed out.
Reactions to the vaccine are localized, such as pain and skin redness at the vaccination site, she added.
The Pfizer vaccine booster should also be given at least six months after the primary vaccination to people aged 18 years and above, according to Lukito.
The effects of the vaccine based on the mRNA platform are generally local in nature, such as pain at the administration site, headache, muscle ache, and fever, she added.
Related news: Jayapura city gov't expedites COVID-19 vaccination of elderly
Translator: Martha H, Azis Kurmala
Editor: Rahmad Nasution
Copyright © ANTARA 2022
